Zusammenfassung
Das Neuroblastom ist ein embryonaler Tumor des Kindesalters. Primärtumoren liegen fast ausschließlich retroperitoneal oder abdominal. Neuroblastome produzieren Katecholamine, die als Tumormarker genutzt werden. Die MIBG-Tumorszintigraphie erlaubt neben Sonographie/Magnetresonanztomographie eine spezifische Tumordarstellung. Bei jungen Patienten werden nicht selten Spontanregressionen beobachtet, während die Überlebenschancen älterer Patienten trotz intensiver Behandlung schlechter sind. Die Therapie des Neuroblastoms muss deshalb risikoadaptiert erfolgen. Das 5-Jahres-Überleben erreichte in Studie NB97 in der Beobachtungsgruppe 96±1%, in der mittleren Risikogruppe 89±3% und in der Hochrisikogruppe 50±3%.
Abstract
Neuroblastoma is an embryonal tumour of childhood. Primary tumours are localized retroperitoneally or abdominally. Neuroblastoma produce catecholamine metabolites which are used as tumour markers. MIBG scintigraphy in addition to ultrasound and nuclear magnetic resonance tomography allow specific imaging of the tumour tissue. In young patients, spontaneous remissions are not uncommon, whereas the outcome in older children is poor despite intensive treatment. Therefore, the treatment of neuroblastoma must be risk adapted. The 5 year overall survival rates in the German NB97 trial were 96±1% in the observation group, 89±3% in the median risk group, and 50±3% in the high risk group.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Berthold F, Simon T (2005) Clinical presentation. In: Cheung NV, Cohn SL (eds) Neuroblastoma. Springer, Berlin Heidelberg New York, Chap 7, pp 63–85
Berthold F, Kremens B, Simon T et al. (2003) Stem cell transplantation vs. maintenance chemotherapy in neuroblastoma: a randomized trial of the GPOH group (abstract). Med Pediatr Oncol 41: 286
Brodeur GM, Pritchard J, Berthold F et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477
Guo C, White PS, Weiss MJ et al. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18: 4948–4957
Hero B, Graf N, Simon T et al. (2002) Neuroblastoma preoperatively treated as nephroblastoma: does inadequate therapy worsen the prognosis? Klin Padiatr 214: 157–161
Maris JM, Weiss MJ, Guo C et al. (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 18: 1888–1899
Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341: 1165–1173
Schilling FH, Spix C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346: 1047–1053
Shimada H, Ambros IM, Dehner LP et al. (1999) Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86: 349–363
Shimada H, Ambros IM, Dehner LP et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86: 364–372
Simon T, Hero B, Faldum A et al. (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22: 3549–3557
Simon T, Spitz R, Faldum A et al. (2004) New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26: 791–796
Spitz R, Hero B, Westermann F et al. (2002) Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 34: 299–305
Spitz R, Hero B, Ernestus K et al. (2003) Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4 s neuroblastoma. Clin Cancer Res 9: 52–58
von Schweinitz D, Hero B, Berthold F (2002) The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12: 402–409
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simon, T. Neuroblastom. Urologe [A] 44, 543–555 (2005). https://doi.org/10.1007/s00120-005-0821-9
Issue Date:
DOI: https://doi.org/10.1007/s00120-005-0821-9